| Schedule of Segment Loss, Including Significant Segment Expenses |
The table below is a summary of the segment loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Revenue: | | | | | | | | | Product Revenue, net | $ | 45,672 | | | $ | 20,923 | | | $ | 71,890 | | | $ | 29,905 | | | License Revenue | 17 | | | — | | | 17 | | | — | | | Total revenue, net | 45,689 | | | 20,923 | | | 71,907 | | | 29,905 | | Less: | | | | | | | | Cost of sales | (20,468) | | | (24,445) | | | (45,036) | | | (42,396) | Research and clinical development | (12,236) | | | (16,069) | | | (23,191) | | | (29,120) | | | Product delivery | (11,641) | | | (4,392) | | | (19,378) | | | (9,965) | | Commercial and Medical affairs | (17,318) | | | (15,558) | | | (35,737) | | | (31,955) | | | Support functions | (18,613) | | | (18,927) | | | (38,843) | | | (36,823) | | Other segment expenses, net (1) | (9,251) | | | (2,749) | | | (13,073) | | | (6,103) | | | Total operating expenses | (89,527) | | | (82,140) | | | (175,258) | | | (156,362) | | | Operating loss | (43,838) | | | (61,217) | | | (103,351) | | | (126,457) | | | Other income, net | 181 | | | 135 | | | 281 | | | 262 | | | Foreign exchange gains (losses), net | 460 | | | 1,499 | | | (2,207) | | | 2,680 | | | Interest income | 1,877 | | | 5,234 | | | 4,346 | | | 11,371 | | Interest expense, net | 2,674 | | | 6,829 | | | (8,450) | | | (3,314) | | Income tax expenses | (465) | | | (397) | | | (1,328) | | | (2,623) | | | Segment and consolidated net loss | $ | (39,111) | | | $ | (47,917) | | | $ | (110,709) | | | $ | (118,081) | | | (1) Other segment expenses, net include United Kingdom research and development tax credits, depreciation, amortization and share-based compensation expenses. |
|